Helus Pharma Inc. (HELP) Stock Forecast & Price Target

Helus Pharma Inc. (HELP) has an ST Score of 62.3 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate HELP a Buy, with a price target of $22.00 (+101.1% vs the current price). Our ST Score grades it B (62.3/100). The ST Score is a data-driven signal, not a recommendation.

Valuation A, Profitability C-, Financial Strength A+, Momentum A-, Growth C, Forecast B+.

Helus Pharma Inc. (HELP) earns a valuation grade of A, measured against Medical - Pharmaceuticals peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Helus Pharma Inc. (HELP) earns a growth grade of C, measured against Medical - Pharmaceuticals peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Helus Pharma Inc. (HELP) earns a profitability grade of C-, measured against Medical - Pharmaceuticals peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Helus Pharma Inc. (HELP) earns a financial strength grade of A+, measured against Medical - Pharmaceuticals peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Helus Pharma Inc. (HELP) is $22.00 from 4 analysts, which is +101.1% versus the recent price of $10.94.

Helus Pharma Inc. (HELP) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.